Phase 5 · Growth-hormone axis

Ipamorelin vs Sermorelin

Both are synthetic signals intended to stimulate pituitary growth-hormone release, but sermorelin has a historical, discontinued U.S. pediatric drug product while ipamorelin has no FDA-approved drug product and neither is established for healthy-aging, physique, or recovery claims.

The short answer

Different does not automatically mean better.

Side AIpamorelin

Side BSermorelin

Side-by-side

What actually separates them

Compare

Ipamorelin

Sermorelin

Identity

IpamorelinA synthetic growth-hormone secretagogue peptide.

SermorelinA 29-amino-acid growth-hormone–releasing hormone (GHRH) analog.

Mechanism

IpamorelinActivates the ghrelin/GHSR pathway to prompt GH release.

SermorelinActivates the pituitary GHRH receptor to prompt GH release.

Evidence

IpamorelinSmall, older human pharmacology work shows short-term GH release; meaningful clinical outcomes are not established.

SermorelinOlder pediatric studies supported its historical indication; this is not evidence for adult wellness use.

U.S. status

IpamorelinNo FDA-approved ipamorelin drug product; FDA flags potential compounding safety concerns.

SermorelinGeref was FDA-approved for pediatric GH deficiency/growth failure but discontinued; that does not make currently marketed sermorelin products FDA-approved.

Main studied context

IpamorelinHealthy-volunteer GH pharmacology.

SermorelinPediatric GH deficiency/growth failure and GH-axis evaluation.

Key limitation

IpamorelinNo robust evidence for chronic use or for sleep, fat loss, muscle gain, or longevity.

SermorelinHistorical approval and older studies do not validate contemporary compounded formulations or uses outside the former pediatric indication.

Evidence check

Known, unknown, and easy to misread

What the evidence shows

An ipamorelin study in healthy male volunteers characterized dose-related GH release after brief IV infusion; it did not test long-term clinical outcomes.

What it does not prove

Sermorelin’s former U.S. product was discontinued; regulatory history is not the same as current product approval or quality assurance.

How to read it

GH release depends on pituitary function, age, adiposity, sleep, illness, and other physiology; a biomarker response is not proof of benefit.

Beginner bottom line

Quick questions

Frequently asked questions

Is ipamorelin FDA-approved?

No FDA-approved ipamorelin drug product is available in the U.S.

Is sermorelin currently FDA-approved?

Geref had FDA approval historically but was discontinued; do not assume this approval applies to a current compounded or online product.

Are these treatments for adult GH deficiency?

Adult GH deficiency requires specialist assessment; these comparisons do not establish either peptide as a replacement for an approved, individualized therapy.

Check the evidence

Primary and official sources

Want to examine the evidence with the community?

Bring a study, ask a focused question, or compare interpretations in Research Discussions.

Visit Research Discussions